Michelle E. Kimple

Dr. Michelle E. Kimple

University of Wisconsin-Madison
+1

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Current Protocols in Protein Science
Verified
Journal Article
Open access
PDF file
MKMichelle E. Kimple
Michelle E. Kimple
ABAllison L. Brill
Allison L. Brill
RPRenee L. Pasker
Renee L. Pasker
Addition of an affinity tag is a useful method for differentiating recombinant proteins expressed in bacterial and eukaryotic expression systems from the background of total cellular proteins, as well as for detecting protein‐protein interactions. This overview describes the historical basis for the development of affinity tags, affinity tags that are commonly used today, how to choose an appropriate affinity tag for a particular purpose, and several recently developed affinity tag technologies that may prove useful in the near future. Curr. Protoc. Protein Sci. 73:9.9.1‐9.9.23. © 2013 by John Wiley & Sons, Inc.

20 May 2013 in Diabetes
Verified
Journal Article
Open access
PDF file
MKMichelle E. Kimple
Michelle E. Kimple
MKMark P. Keller
Mark P. Keller
MRMary R. Rabaglia
Mary R. Rabaglia
RPRenee L. Pasker
Renee L. Pasker
JNJoshua C. Neuman
Joshua C. Neuman
AAAlan D. Attie
Alan D. Attie
BTBR mice develop severe diabetes in response to genetically induced obesity due to a failure of the β-cells to compensate for peripheral insulin resistance. In analyzing BTBR islet gene expression patterns, we observed that Pgter3, the gene for the prostaglandin E receptor 3 (EP3), was upregulated with diabetes. The EP3 receptor is stimulated by prostaglandin E2 (PGE2) and couples to G-proteins of the Gi subfamily to decrease intracellular cAMP, blunting glucose-stimulated insulin secretion (GSIS). Also upregulated were several genes involved in the synthesis of PGE2. We hypothesized that increased signaling through EP3 might be coincident with the development of diabetes and contribute to β-cell dysfunction. We confirmed that the PGE2-to-EP3 signaling pathway was active in islets from confirmed diabetic BTBR mice and human cadaveric donors, with increased EP3 expression, PGE2 production, and function of EP3 agonists and antagonists to modulate cAMP production and GSIS. We also analyzed the impact of EP3 receptor activation on signaling through the glucagon-like peptide (GLP)-1 receptor. We demonstrated that EP3 agonists antagonize GLP-1 signaling, decreasing the maximal effect that GLP-1 can elicit on cAMP production and GSIS. Taken together, our results identify EP3 as a new therapeutic target for β-cell dysfunction in T2D.

20 June 2014 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
MKMichelle E. Kimple
Michelle E. Kimple
JNJoshua C Neuman
Joshua C Neuman
ALAmelia K Linnemann
Amelia K Linnemann
PCPatrick Casey
Patrick Casey
The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): a costly chronic disease and serious public health problem. The underlying cause of T2DM is a failure of the beta cells of the pancreas to continue to produce enough insulin to counteract insulin resistance. Most current T2DM therapeutics do not prevent continued loss of insulin secretion capacity, and those that do have the potential to preserve beta cell mass and function are not effective in all patients. Therefore, developing new methods for preventing and treating obesity and T2DM is very timely and of great significance. There is now considerable literature demonstrating a link between inhibitory guanine nucleotide-binding protein (G protein) and G protein-coupled receptor (GPCR) signaling in insulin-responsive tissues and the pathogenesis of obesity and T2DM. These studies are suggesting new and emerging therapeutic targets for these conditions. In this review, we will discuss inhibitory G proteins and GPCRs that have primary actions in the beta cell and other peripheral sites as therapeutic targets for obesity and T2DM, improving satiety, insulin resistance and/or beta cell biology.

25 June 2014 in Journal of Visualized Experiments
Verified
Journal Article
Open access
PDF file
JNJoshua C. Neuman
Joshua C. Neuman
NTNathan A. Truchan
Nathan A. Truchan
JJJamie W. Joseph
Jamie W. Joseph
MKMichelle E. Kimple
Michelle E. Kimple
Assaying in vitro β-cell function using isolated mouse islets of Langerhans is an important component in the study of...

13 February 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
JNJoshua C. Neuman
Joshua C. Neuman
MSMichael D. Schaid
Michael D. Schaid
ABAllison L. Brill
Allison L. Brill
RFRachel Fenske
Rachel Fenske
CKCarly R. Kibbe
Carly R. Kibbe
MKMichelle E. Kimple
Michelle E. Kimple
Prostaglandin E2 (PGE2) is derived from arachidonic acid, whereas PGE3 is derived from eicosapentaenoic acid (EPA) using the same downstream metabolic enzymes. Little is known about the impact of EPA and PGE3 on β-cell function, particularly in the diabetic state. In this work, we determined that PGE3 elicits a 10-fold weaker reduction in glucose-stimulated insulin secretion through the EP3 receptor as compared with PGE2. We tested the hypothesis that enriching pancreatic islet cell membranes with EPA, thereby reducing arachidonic acid abundance, would positively impact β-cell function in the diabetic state. EPA-enriched islets isolated from diabetic BTBR Leptinob/ob mice produced significantly less PGE2 and more PGE3 than controls, correlating with improved glucose-stimulated insulin secretion. NAD(P)H fluorescence lifetime imaging showed that EPA acts downstream and independently of mitochondrial function. EPA treatment also reduced islet interleukin-1β expression, a proinflammatory cytokine known to stimulate prostaglandin production and EP3 expression. Finally, EPA feeding improved glucose tolerance and β-cell function in a mouse model of diabetes that incorporates a strong immune phenotype: the NOD mouse. In sum, increasing pancreatic islet EPA abundance improves diabetic β-cell function through both direct and indirect mechanisms that converge on reduced EP3 signaling.

12 April 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
KBKarin J. Bosma
Karin J. Bosma
CKCecilia E. Kaiser
Cecilia E. Kaiser
MKMichelle E. Kimple
Michelle E. Kimple
MGMaureen A Gannon
Maureen A Gannon
Arachidonic acid (AA) is a polyunsaturated 20-carbon fatty acid present in phospholipids in the plasma membrane. The three primary pathways by which AA is metabolized are mediated by cyclooxygenase (COX) enzymes, lipoxygenase (LOX) enzymes, and cytochrome P450 (CYP) enzymes. These three pathways produce eicosanoids, lipid signaling molecules that play roles in biological processes such as inflammation, pain, and immune function. Eicosanoids have been demonstrated to play a role in inflammatory, renal, and cardiovascular diseases as well type 1 and type 2 diabetes. Alterations in AA release or AA concentrations have been shown to affect insulin secretion from the pancreatic beta cell, leading to interest in the role of AA and its metabolites in the regulation of beta-cell function and maintenance of beta-cell mass. In this review, we discuss the metabolism of AA by COX, LOX, and CYP, the roles of these enzymes and their metabolites in beta-cell mass and function, and the possibility of targeting these pathways as novel therapies for treating diabetes.